HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
N-acetylmuramyl-threonyl-isoglutamine
Also Known As:
SAF-m; THR-MDP
Networked:
3
relevant articles (
0
outcomes,
2
trials/studies)
Bio-Agent Context: Research Results
Carbohydrates: 22023
Amino Sugars: 110
Muramic Acids: 28
Acetylmuramyl-Alanyl-Isoglutamine: 467
N-acetylmuramyl-threonyl-isoglutamine: 3
Sugar Acids: 4
Muramic Acids: 28
Acetylmuramyl-Alanyl-Isoglutamine: 467
N-acetylmuramyl-threonyl-isoglutamine: 3
Amino Acids, Peptides, and Proteins: 1
Peptides: 82426
Glycopeptides: 1928
Acetylmuramyl-Alanyl-Isoglutamine: 467
N-acetylmuramyl-threonyl-isoglutamine: 3
Related Diseases
1.
Melanoma (Melanoma, Malignant)
09/01/1998 - "
We conducted a Phase IB trial of different doses of a one-to-one composition to Melimmune-1 and Melimmune-2 administered with SAF-m adjuvant in patients with resected melanoma without evidence of metastatic disease.
"
10/01/1998 - "
Twenty-eight stage I-IV high-risk patients with melanoma were immunized with a mixture of variable concentrations of MELIMMUNE-1 and MELIMMUNE-2, along with the adjuvant SAF-m, using two immunization schedules.
"
05/01/1997 - "
Twenty-six patients with metastatic melanoma, 17 of whom had previously received chemotherapy, were given 2 mg of I-Mel-2 and either 100 micrograms (n = 6) or 250 micrograms (n = 20) of SAF-m.
"
05/01/1997 - "
Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus SAF-m.
"
05/01/1997 - "
To determine the toxicity and immunologic activity of an antiidiotype melanoma vaccine that consists of monoclonal antibody I-Mel-2 (MELIMMUNE-2, IDEC Pharmaceuticals, La Jolla, CA) and an immunologic adjuvant SAF-m.
"
2.
Arthralgia (Joint Pain)
05/01/1997 - "
Grade III myalgias/arthralgias and headaches required dose reduction of SAF-m in eight patients at the 250-microgram dose.
"
3.
Headache (Headaches)
05/01/1997 - "
Grade III myalgias/arthralgias and headaches required dose reduction of SAF-m in eight patients at the 250-microgram dose.
"
Related Drugs and Biologics
1.
Vaccines
2.
Monoclonal Antibodies
3.
Immunologic Adjuvants (Immunologic Adjuvant)
Related Therapies and Procedures
1.
Immunotherapy
2.
Drug Therapy (Chemotherapy)
3.
Drug Tapering